Use of GalaFlex in Ptotic Breast
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.)
- Be at least 21 years of age.
- Be willing and able to comply with the requirements of the protocol.
- Be willing to refrain from participating in any other investigational interventional study while enrolled in this study.
- Female subjects must have a negative pregnancy test within the last 24 hours timeline and have no intentions of becoming pregnant during participation in the study, or be sterilized.
Exclusion Criteria:
- Subjects unwilling or unable to give written consent to participate in the investigation or unable to comply with the requirements of the protocol.
- Subjects with known severe allergies manifested by a history of anaphylaxis or allergy to GalaFLEX mesh, poly-4-hydroxybutyrate (P4HB), a resorbable polymer, or silicone.
- Subjects with known active infection and/or who received or are targeted to receive immunosuppressive therapy over the course of the study (such as rheumatoid arthritis).
- Subjects who received any experimental drug or device within the previous three months.
- Female subjects who were pregnant or lactating or were intending to become pregnant during the period of the study, or who would not use an adequate method of contraception (contraceptive pill, intra-uterine device) for the duration of the study.
- Possessed any psychological condition, or was under treatment for any condition which, in the opinion of the Investigator and/or consulting physicians(s), would constitute an unwarranted risk.
- Have collagen-vascular, connective disease, or bleeding disorders.
- Have a BMI that is greater than or equal to 30.
- Have any disease, including uncontrolled diabetes, which is clinically known to impact wound healing ability.
- Have an autoimmune disease, an immune deficiency, or is on immune suppression drugs.
- Currently have an alcohol/substance abuse problem or have had a relapse within 1 year prior to screening visit.
- Have concomitant unrelated condition of breast/chest wall/skin.
- Have undergone previous breast surgery with the exception of breast biopsy.
- Subject is currently a smoker or is a prior smoker who quit in the last 12 months.
- Currently involved with claims for, or is accepting workers compensation.
Currently engaged in medical malpractice litigation.
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Breast Mastopexy with or without reduction using GalaFlex Mesh
Breast mastopexy with or without reduction, using GalaFLEX mesh
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary outcome for study success is defined as ptosis correction and maintenance of the surgical correction
Time Frame: 1year
|
Correction of ptosis at 3 months must be Grade 0, Pseudoptosis, or Grade 1, and maintenance of ptosis correction at 12 months is demonstrated by a classification of ptosis Grade 1 or less
|
1year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long term visibility: Mammography and ultrasound will be used to evaluate the presence of the mesh or potential for mesh interference in evaluation of the breast tissue.
Time Frame: 1 year
|
Long term visibility
|
1 year
|
|
Investigator satisfaction with the surgical implantation/usage of GalaFLEX Scaffold based on a satisfaction questionnaire completed at procedural and follow up timepoints
Time Frame: 1 year
|
To determine the role that GalaFLEX scaffold plays in MD's perception of the ability to obtain a successful result, MD's provide assessments of the surgical procedures such as mesh handling, ease of placement.
At follow up timepoints, a satisfaction questionnaire is completed to assess satisfaction with overall procedural results
|
1 year
|
|
Patient satisfaction based on a survey
Time Frame: 1 year
|
Patient satisfaction
|
1 year
|
|
Adverse event summary
Time Frame: 1 year
|
Adverse Events reported in the study will be evaluated for attribution to the devoce/procedure
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Connie Garrison, Tepha, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CP-1050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.